A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
Superficial Basal Cell Carcinoma · Nodular Basal Cell Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2022, none posted yet
Counts until it's fixed
- +4.7
2 insiders sold shares within a month
Since Sep 1, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 32 (planned)
- Started
- Jun 30, 2021
- Main results expected
- May 2022
- Fully finished
- Jun 2022
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of treatment-emergent AEs (TEAEs) and serious TEAEs (STEAEs).
Measured over: Through study completion - an average of 16 weeks
Vital signs - proportion of patients with abnormal clinical significant measurements
Measured over: Up to completion of treatment period - up to 5 weeks
Pain assessments- Proportion of patients with clinical significant elevation in NPRS score
Measured over: Up to completion of treatment period - up to 5 weeks
Proportion of subjects discontinuing a treatment due to TEAEs, assessed over the entire course of the treatment.
Measured over: Up to completion of treatment period - up to 5 weeks
Proportion of subjects that requested to discontinue the treatment
Measured over: Up to completion of treatment period - up to 5 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2022-05-01, no fading
- insider_selling_cluster: base 10, now 4.7, since 2026-09-01, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05157763 · record last updated 2021-12-15 · checked 2026-11-09 15:42 UTC